Current Vascular Pharmacology
Title: Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Volume: 6 Issue: 3
Author(s): Kosmas I. Paraskevas, Nikolaos Bessias, Dimitrios Maras, Christos D. Gekas and Vassilios Andrikopoulos
Affiliation:
Export Options
About this article
Cite this article as:
Paraskevas I. Kosmas, Bessias Nikolaos, Maras Dimitrios, Gekas D. Christos and Andrikopoulos Vassilios, Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ], Current Vascular Pharmacology 2008; 6 (3) . https://dx.doi.org/10.2174/157016108784912000
DOI https://dx.doi.org/10.2174/157016108784912000 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Premature Frailty in HIV-Infected Persons; Another Manifestation of HIV-Related Accelerated Aging
Current Aging Science Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine Editorial [Hot Topic: COX-2 Inhibition in Gastroenterology and Rheumatolgy:Current Challenges and Perspectives for the Future (Executive Editor: Angel Lanas)]
Current Pharmaceutical Design NPY and Cardiac Diseases
Current Topics in Medicinal Chemistry Thoughtful Insights into the Therapeutic Armamentarium of Chalcones: 10 Years of Glorious Journey
Current Bioactive Compounds Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)]
Current Pharmaceutical Design Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design EarlyVascularAgeing and Hypertension -A New Model for Understanding Cardiovascular Risk
Current Hypertension Reviews Liver X Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Statins in Stroke Prevention: Present and Future
Current Pharmaceutical Design Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design Editorial (Forward Look: Tenth Anniversary of the Human Genome Sequence and 21st Century Postgenomics Global Health - A Close Up on Africa and Womens Health)
Current Pharmacogenomics and Personalized Medicine Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome
Current Pharmaceutical Design Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design